Source comparison
Stacking BPC-157 + KPV — Gut Inflammation: Peptide Comparison
Before starting any stacking protocol for gut inflammation, understanding the distinctions between BPC-157, KPV, and alternative peptides clarifies why this specific combination delivers superior outcomes compared to single-peptide approaches or different stac
This comparison does not assign a generated winner or score.
- Before starting any stacking protocol for gut inflammation, understanding the distinctions between BPC-157, KPV, and alternative peptides clarifies why this specific combination delivers superior outcomes compared to single-peptide approaches or different stacks.
- BPC-157
- VEGF upregulation, angiogenesis, fibroblast migration, nitric oxide stabilisation
- Subcutaneous (systemic distribution to gut via mesenteric circulation)
- 250–500 mcg twice daily
- Oral bioavailability inconsistent due to gastric degradation; does not address upstream immune activation
- Essential for structural repair but insufficient alone for immune-driven inflammation. Requires pairing with NF-κB inhibitor
- KPV
- NF-κB translocation inhibition, IKK blockade, mast cell stabilisation
- Oral (concentrates in intestinal mucosa)
- 500–1,000 mcg three times daily
- Does not accelerate tissue repair; purely immune-modulatory
- Prevents further damage but does not rebuild existing lesions. Most effective when stacked with angiogenic peptide
- Thymosin Beta-4 (TB-500)
- Actin sequestration, cell migration, anti-fibrotic effects
- Subcutaneous
- 2–5 mg twice weekly
- Broader systemic effects; less gut-specific than BPC-157; higher cost per protocol
- Valid alternative to BPC-157 for tissue repair but lacks the gastric juice-derived specificity and published gut inflammation data
- LL-37
- Antimicrobial peptide, immune modulation, wound healing
- Oral or subcutaneous
- 2–5 mg daily
- Primarily antimicrobial; inflammation reduction is secondary; expensive
- Useful for gut dysbiosis-driven inflammation but does not address sterile inflammatory conditions or structural damage
- GHK-Cu
- Collagen synthesis, anti-inflammatory via TGF-β modulation
- 1–3 mg daily
- Weaker angiogenic effect than BPC-157; copper toxicity concern at high chronic doses
- Supports extracellular matrix remodelling but inferior to BPC-157 for acute mucosal lesions